Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results

    January 2026 in “ Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) ”
    Piraccini BM, Cedirian S, Pampaloni F, Rapparini L, Quadrelli F, Bruni F, Ala L, Acri MC, Rossi A., Pellacani G., F Lacarrubba, Dall'Oglio F, G Micali, Foggia L, Cantelli M, Nappa P, Diluvio L, Bianchi L, Luigi N, Bolzon A, Peris K, Caldarola G, G Girolomoni, Marangoni F, Bellinato F, Gisondi P, Silvi G, Prignano F, Pimpinelli N, C. Tomasini, Barruscotti S, Simonetti O, de Simoni E, Ambrogio F, Foti C, Boccaletti V, Fraghì A, Marzano A.V., Mattioli MA, Ferrucci S, A Sechi, Valtellini L, Barbareschi M, Gallo G, Ribero S, Quaglino P, Di Corteranzo IG, Balestri R, Pagliarello C, Caposiena RD, Zalaudek I, Vagnozzi E, Fargnoli MC, Caponio C, Rubegni P, Cinotti E, Trovato E, M Romanelli, Dini V, Manzo Margiotta F, Feliciani C, De Felici Del Giudice MB, Atzori L Mantovani L, Sanna S, Lembo S, Raimondo A, Magnano M, Argenziano G., Babino G, Fulgione E, Rongioletti F, Pesce N, Guida S, Guglielmo A, Schettini N, M Starace
    This study assessed the effectiveness and safety of baricitinib, a JAK inhibitor, in 253 Italian adults with severe alopecia areata over 48 weeks. Results showed that 63.2% of patients achieved a SALT score of ≤20, indicating significant hair regrowth, with the mean SALT score decreasing from 93.7 to 26.5. Improvements were also noted in trichoscopic findings and patient-reported quality of life measures, with significant reductions in Skindex-16 and HADS scores. Adverse events occurred in 9.4% of patients. The study confirms baricitinib's effectiveness in promoting hair regrowth and enhancing psychological well-being in severe AA patients.
    Discuss this study in the Community →